Voices

Guru Sonpavde: Cutting-Edge and Emerging Therapies Reported at ASCO25 and GU25

Guru Sonpavde/adventhealth.com

Aug 19, 2025, 18:05

Guru Sonpavde: Cutting-Edge and Emerging Therapies Reported at ASCO25 and GU25

Guru Sonpavde, GU Oncology and Phase I Clinical Trials Director, Chair of Bladder Cancer Research at AdventHealth Central Florida, Professor of Medicine at the University of Central Florida, and at Loma Linda University Health, shared a post on LinkedIn:

“Bladder cancer webinar – honored to participate as speaker from AdventHealth Central Florida Cancer Institute – sponsored by Dr. Vishwanath Sathyanarayanan, CPOEM Foundation – along with a great speaker lineup including Daniel Petrylak, Dr. Ashwin Mallya, we discuss cutting-edge and emerging therapies reported at ASCO25 and GU25 – look for exciting data at ESMO25.”

M	T	W	T	F	S	S
1	2	3	4	5	6	7
8	9	10	11	12	13	14
15	16	17	18	19	20	21
22	23	24	25	26	27	28
29	30

Voices

OncoDaily

Voices

Guru Sonpavde: Cutting-Edge and Emerging Therapies Reported at ASCO25 and GU25